IRCT20210519051345N1尚未招募未知
In vivo Bioequivalence study of Ticagrelor 90 mg Tablet manufactured by Sobhan Daroo Co. on 24 volunteers compared with reference product
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25 years 至 55 years（—）
- 性别
- Male
入选标准
- •Being Healthy without any Heart, liver and kidney diseases
排除标准
- •Having any kind of illnesses
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Ticagrelor® tablet with brand drugs (BRILINTA® AstraZeneca UK).IRCT20200105046010N31ABIDI Pharmaceutical Company24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Ticagrelor 90 mg F.C. Tablet and Brilinta® 90 mg F.C. Tablet formulations.ong term (current) use of antithrombotics/antiplatelets.Long term (current) use of antithrombotics/antiplateletsZ79.02IRCT20180620040164N54Zist Arvand Pharme Ltd.24
招募中
不适用
In-vivo Bioequivalence Test of Ticagrelor® tablet with brand drugs (BRILINTA® AstraZeneca UK).IRCT20200105046010N28ARENA Pharmaceutical Company24
已完成
不适用
Bioequivalence study of Ticagrelor 90mgIRCT20200623047902N9Kimia Ara Heram company24
进行中（未招募）
1 期
Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy VolunteersEUCTR2012-005514-18-GBSheffield Teaching Hospitals NHS Foundation Trust30